Inhibikase appoints Mark Iwicki as CEO; founder Milton Werner resigns

Inhibikase Therapeutics, Inc.

Milton Werner resigned as CEO/board member effective Feb 13, 2025; will consult through May 13, 2025 at $44,583/month.
Mark Iwicki appointed CEO, President and director effective Feb 14, 2025; base salary $710K, bonus up to 60%, options for 15.1M shares.
Amit Munshi named independent Chair of the Board, replacing Roberto Bellini who remains a director.
Company advancing IkT-001Pro in Phase 2b trial with $110M from October financing; new CEO has PAH expertise.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Milton H. Werner

Chief Executive Officer

IKT · Inhibikase Therapeutics, Inc.

Effective: 2025-02-13
Successor: Mark Iwicki
Filed: February 18, 2025, 6:59 PM ET

Effective February 13, 2025, Milton H. Werner, Ph.D. resigned as President, Chief Executive Officer and principal executive officer of Inhibikase Therapeutics, Inc. (the “Company”) and as a member of the Board of Directors (the “Board”) of the Company (the “Resignation”).

Appointed

Mark Iwicki

Chief Executive Officer

IKT · Inhibikase Therapeutics, Inc.

Effective: 2025-02-14
Filed: February 18, 2025, 6:59 PM ET

Effective February 14, 2025, the Board appointed Mark Iwicki as President, Chief Executive Officer and principal executive officer of the Company (the “Appointment”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Milton H. Werner resigned as Chief Executive Officer at Inhibikase Therapeutics, Inc..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

Effective February 13, 2025, Milton H. Werner, Ph.D. resigned as President, Chief Executive Officer and principal executive officer of Inhibikase Therapeutics, Inc. (the “Company”) and as a member of the Board of Directors (the “Board”) of the Company (the “Resignation”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Iwicki was appointed as Chief Executive Officer at Inhibikase Therapeutics, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

Effective February 14, 2025, the Board appointed Mark Iwicki as President, Chief Executive Officer and principal executive officer of the Company (the “Appointment”).

View on SEC.gov

Inhibikase Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-028188

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.